FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281755116> ?p ?o ?g. }

• W4281755116 endingPage "109645" @default.
• W4281755116 startingPage "109645" @default.
• W4281755116 abstract "Background: It is well established that diabetic nephropathy (DN) is the first cause of end-stage renal disease (ESRD) in developed and developing countries. Serum uric acid (SUA) level has been widely recognized as a risk factor for DN development because oxidants are produced that can play a key role in renal injury during UA synthesis. Recently, a randomized, controlled trial (RCT) showed that in Multi-ethnic patients with a high risk of progression and stage 3-4 CKD in Australia and New Zealand, SUA lowering treatment using allopurinol could not significantly attenuate the drop of eGFR as compared with placebo, which is somewhat intriguing. Therefore, the association between SUA and renal outcome in type 2 diabetes mellitus (T2DM) and DN patients remains to be elucidated in more detail. Aim: To investigate the relationship between SUA level and renal outcome in patients with T2DM and diabetic nephropathy (DN). Method: A total of 393 Chinese patients with T2DM and biopsy-proven DN and followed at least one year were enrolled in this study. Patients were stratified by the quartiles of baseline level of SUA: Q1 group286.02± 46.66 μmol/L (n=98); Q2 group: 358.23±14.03 μmol/L (n=99); Q3 group: 405.50±14.59 μmol/L (n=98) and Q4 group: 499.14±56.97 μmol/L (n=98). Renal outcome was defined by progression to end stage renal disease (ESRD). Kaplan-Meier survival analysis and Cox proportional hazards model were used to analyze the association between SUA quartiles and the renal outcomes. Results: During the median 3-year follow-up period, there were 173 ESRD outcome events (44.02%) during follow-up. No significant difference among SUA level the risk of progression of DN (P=0.747) was shown in the Kaplan-Meier survival analysis. In multivariable-adjusted model, HRs for developing ESRD were 1.364(0.621-2.992; p=0.439), 1.518(0.768-3.002; p=0.230) and 1.411(0.706-2.821; p=0.330) for the Q2, Q3 and Q4, respectively, in comparison with the Q1 (P=0.652). Discussion: No significant association between SUA level and renal outcome of ESRD in Chinese patients with T2DM and DN was found in our study. Besides, the role of uric acid-lowering therapy in delaying DN progression and improve ESRD outcome had not yet been proven. Further study was needed to clarify the renal benefit of the uric acid-lowering therapy in the treatment of DN." @default.
• W4281755116 created "2022-06-13" @default.
• W4281755116 creator A5028973847 @default.
• W4281755116 creator A5047568354 @default.
• W4281755116 date "2022-04-01" @default.
• W4281755116 modified "2023-10-18" @default.
• W4281755116 title "IDF21-0282 Association between Serum Uric Acid and Renal Outcome in Patients with Biopsy-confirmed Diabetic Nephropathy" @default.
• W4281755116 doi "https://doi.org/10.1016/j.diabres.2022.109645" @default.
• W4281755116 hasPublicationYear "2022" @default.
• W4281755116 type Work @default.
• W4281755116 citedByCount "0" @default.
• W4281755116 crossrefType "journal-article" @default.
• W4281755116 hasAuthorship W4281755116A5028973847 @default.
• W4281755116 hasAuthorship W4281755116A5047568354 @default.
• W4281755116 hasBestOaLocation W42817551161 @default.
• W4281755116 hasConcept C126322002 @default.
• W4281755116 hasConcept C134018914 @default.
• W4281755116 hasConcept C2778653478 @default.
• W4281755116 hasConcept C2779134260 @default.
• W4281755116 hasConcept C2779881121 @default.
• W4281755116 hasConcept C2779922275 @default.
• W4281755116 hasConcept C2780091579 @default.
• W4281755116 hasConcept C2781184683 @default.
• W4281755116 hasConcept C3019040382 @default.
• W4281755116 hasConcept C44249647 @default.
• W4281755116 hasConcept C555293320 @default.
• W4281755116 hasConcept C68443243 @default.
• W4281755116 hasConcept C71924100 @default.
• W4281755116 hasConcept C90924648 @default.
• W4281755116 hasConceptScore W4281755116C126322002 @default.
• W4281755116 hasConceptScore W4281755116C134018914 @default.
• W4281755116 hasConceptScore W4281755116C2778653478 @default.
• W4281755116 hasConceptScore W4281755116C2779134260 @default.
• W4281755116 hasConceptScore W4281755116C2779881121 @default.
• W4281755116 hasConceptScore W4281755116C2779922275 @default.
• W4281755116 hasConceptScore W4281755116C2780091579 @default.
• W4281755116 hasConceptScore W4281755116C2781184683 @default.
• W4281755116 hasConceptScore W4281755116C3019040382 @default.
• W4281755116 hasConceptScore W4281755116C44249647 @default.
• W4281755116 hasConceptScore W4281755116C555293320 @default.
• W4281755116 hasConceptScore W4281755116C68443243 @default.
• W4281755116 hasConceptScore W4281755116C71924100 @default.
• W4281755116 hasConceptScore W4281755116C90924648 @default.
• W4281755116 hasLocation W42817551161 @default.
• W4281755116 hasOpenAccess W4281755116 @default.
• W4281755116 hasPrimaryLocation W42817551161 @default.
• W4281755116 hasRelatedWork W104068484 @default.
• W4281755116 hasRelatedWork W1563850031 @default.
• W4281755116 hasRelatedWork W1972106995 @default.
• W4281755116 hasRelatedWork W1983927182 @default.
• W4281755116 hasRelatedWork W2129721911 @default.
• W4281755116 hasRelatedWork W2262162404 @default.
• W4281755116 hasRelatedWork W2357968536 @default.
• W4281755116 hasRelatedWork W2440867061 @default.
• W4281755116 hasRelatedWork W3035848550 @default.
• W4281755116 hasRelatedWork W1720298151 @default.
• W4281755116 hasVolume "186" @default.
• W4281755116 isParatext "false" @default.
• W4281755116 isRetracted "false" @default.
• W4281755116 workType "article" @default.